Biocardia receives no objection letter from health canada, enabling company to expand cardiamp cell therapy heart failure trial into canada

Sunnyvale, calif., march 01, 2022 (globe newswire) -- biocardia®, inc. (nasdaq: bcda), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a no objection letter from health canada, the country's health services agency, allowing the cardiamp® heart failure trial to expand into canada. the phase iii pivotal trial is currently enrolling patients in the u.s.
BCDA Ratings Summary
BCDA Quant Ranking